MHRAapproval72% confidence
Clinical trials for medicines: modifying a clinical trial approval
Source: MHRA
Why This Matters
Why this matters: illustrates how regulators handled a comparable approval decision relevant to Cipla.
Regulatory Analysis
Guidance on the various types of modifications that can be made to a clinical trial approval.
Supporting Context
- Therapeutic area
- Neurology · Migraine
- Sub-indication
- General
Related signal: Cipla's ANDA214209 for Sumatriptan Receives Abbreviated Approval from FDA